Literature DB >> 11772981

Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

V Schmitz1, C Qian, J Ruiz, B Sangro, I Melero, G Mazzolini, I Narvaiza, J Prieto.   

Abstract

Gene therapy has emerged as a powerful and very plastic tool to regulate biological functions in diseased tissues with application in virtually all medical fields. An increasing number of experimental and clinical studies underline the importance of genes as curative agents in the future. However, intense research is needed to evaluate the potential of gene therapy to improve efficacy and minimise the toxicity of the procedure.

Entities:  

Mesh：

Year:  2002        PMID： 11772981      PMCID： PMC1773082          DOI： 10.1136/gut.50.1.130

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  74 in total

Review 1.  The potential of gene therapy in the treatment of hepatocellular carcinoma.

Authors:  C Qian; M Drozdzik; W H Caselmann; J Prieto
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

Review 2.  High-capacity adenoviral vectors for gene transfer and somatic gene therapy.

Authors:  S Kochanek
Journal:  Hum Gene Ther       Date:  1999-10-10       Impact factor: 5.695

3.  Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma.

Authors:  M Drozdzik; C Qian; X Xie; D Peng; R Bilbao; G Mazzolini; J Prieto
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

4.  Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.

Authors:  I Narvaiza; G Mazzolini; M Barajas; M Duarte; M Zaratiegui; C Qian; I Melero; J Prieto
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

5.  Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone.

Authors:  Y Sun; C Qian; D Peng; J Prieto
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

6.  Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level.

Authors:  G Mazzolini; C Qian; I Narvaiza; M Barajas; F Borrás-Cuesta; X Xie; M Duarte; I Melero; J Prieto
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

7.  Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.

Authors:  L Aurisicchio; P Delmastro; V Salucci; O G Paz; P Rovere; G Ciliberto; N La Monica; F Palombo
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation.

Authors:  M Alt; S Eisenhardt; M Serwe; R Renz; J W Engels; W H Caselmann
Journal:  Eur J Clin Invest       Date:  1999-10       Impact factor: 4.686

Review 9.  Gene therapy of viral hepatitis and hepatocellular carcinoma.

Authors:  J Ruiz; C Qian; M Drozdzik; J Prieto
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

Review 10.  Hepatocellular carcinoma.

Authors:  K Okuda
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083
View more
  10 in total

1.  Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.

Authors:  Volker Schmitz; Esther Raskopf; Maria Angeles Gonzalez-Carmona; Annabelle Vogt; Christian Rabe; Ludger Leifeld; Miroslaw Kornek; Tilman Sauerbruch; Wolfgang H Caselmann
Journal:  Gut       Date:  2006-06-29       Impact factor: 23.059

2.  Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Cheng-En Pan; Jing Ye; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 3.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

4.  Evaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model.

Authors:  Gang Wang; Xiaoyan Dong; Wenhong Tian; Yue Lu; Jianyan Hu; Yunfan Liu; Jie Yuchi; Xiaobing Wu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

Review 5.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma.

Authors:  Pei-Yuan Li; Ju-Sheng Lin; Zuo-Hua Feng; Yu-Fei He; He-Jun Zhou; Xin Ma; Xiao-Kun Cai; De-An Tian
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

7.  A potential targeting gene vector based on biotinylated polyethyleneimine/avidin bioconjugates.

Authors:  Xuan Zeng; Yun-Xia Sun; Xian-Zheng Zhang; Si-Xue Cheng; Ren-Xi Zhuo
Journal:  Pharm Res       Date:  2009-06-05       Impact factor: 4.200

8.  Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.

Authors:  Anna D Kosinska; Ejuan Zhang; Mengji Lu; Michael Roggendorf
Journal:  Hepat Res Treat       Date:  2010-09-07

9.  Gene Therapy Applications to Cancer Treatment.

Authors:  Susy M. Scholl; Silke Michaelis; Ray McDermott
Journal:  J Biomed Biotechnol       Date:  2003

10.  HSVtk/GCV system on hepatoma carcinoma cells: Construction of the plasmid pcDNA3.1‑pAFP-TK and targeted killing effect.

Authors:  Yong-Fang Li; Yang-Yang Yuan; Ying-Min Zhang; Na Zhao; Qi Zhang; Fan-Xiu Meng; Ran-Peng Gao; Bao-Feng Yu; Yue-Hong Zhang; Rui Guo; Hai-Long Wang; Jun Xie; Jun Xu; Qin Qin; Xiu-Shan Dong
Journal:  Mol Med Rep       Date:  2017-05-31       Impact factor: 2.952
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.